Upstream Bio Forecast, price target & analysts
Upstream Bio Target price 2026 - Analyst rating & recommendation
Upstream Bio Classifications & Recommendation
Upstream Bio Price Target
| Target Price | $31.11 |
| Price | $5.17 |
| Potential |
501.74%
register free of charge
|
| Number of Estimates | 8 |
|
8 Analysts have issued a price target Upstream Bio 2027 .
The average Upstream Bio target price is $31.11.
This is
501.74%
register free of charge
$78.75
1,423.21%
register free of charge
$15.15
193.04%
register free of charge
|
|
| A rating was issued by 13 analysts: 10 Analysts recommend Upstream Bio to buy, 3 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Upstream Bio stock has an average upside potential 2027 of
501.74%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 2.85 | 2.68 |
| 20.25% | 5.89% | |
| EBITDA Margin | -5,620.00% | -6,477.26% |
| 71.46% | 15.25% | |
| Net Margin | -5,032.98% | -5,990.17% |
| 56.13% | 19.02% |
8 Analysts have issued a sales forecast Upstream Bio 2026 . The average Upstream Bio sales estimate is
This results in the following potential growth metrics:
2 Analysts have issued an Upstream Bio EBITDA forecast 2026. The average Upstream Bio EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
10 Upstream Bio Analysts have issued a net profit forecast 2026. The average Upstream Bio net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -2.66 | -2.93 |
| 78.52% | 10.15% | |
| P/E | negative | |
| EV/Sales | 8.15 |
10 Analysts have issued a Upstream Bio forecast for earnings per share. The average Upstream Bio EPS is
This results in the following potential growth metrics and future valuations:
Current Upstream Bio Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Sep 02 2026 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Aug 14 2026 |
| Truist Securities |
Locked
➜
Locked
|
Locked | Aug 12 2026 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Jun 12 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jun 03 2026 |
| Mizuho |
Locked
➜
Locked
|
Locked | May 14 2026 |
| Evercore ISI Group |
Locked
➜
Locked
|
Locked | Mar 27 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Sep 02 2026 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Aug 14 2026 |
|
Locked
Truist Securities:
Locked
➜
Locked
|
Aug 12 2026 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Jun 12 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jun 03 2026 |
|
Locked
Mizuho:
Locked
➜
Locked
|
May 14 2026 |
|
Locked
Evercore ISI Group:
Locked
➜
Locked
|
Mar 27 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
